Whitney D Gannon1, John W Stokes2, Sarah Bloom3, Wren Sherrill3, Matthew Bacchetta4, Todd W Rice3, Matthew W Semler3, Jonathan D Casey3. 1. Department of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN. Electronic address: whitney.gannon@vumc.org. 2. Department of Thoracic Surgery, Vanderbilt University Medical Center, Nashville, TN. 3. Department of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN. 4. Department of Thoracic Surgery, Vanderbilt University Medical Center, Nashville, TN; Department of Cardiac Surgery, Vanderbilt University Medical Center, Nashville, TN; Department of Biomedical Engineering, Vanderbilt University Medical Center, Nashville, TN.
Abstract
BACKGROUND: Decannulation from venovenous extracorporeal membrane oxygenation (ECMO) at the earliest and safest possible time may improve outcomes and reduce cost. Yet, no prospective studies have compared weaning strategies for liberation from ECMO. RESEARCH QUESTION: Is a protocolized daily assessment of readiness to liberate from venovenous ECMO safe and feasible? STUDY DESIGN AND METHODS: We conducted a prospective, single-arm safety and feasibility study of a protocol for daily assessment of readiness to liberate from venovenous ECMO among consecutive adult patients receiving venovenous ECMO across four ICUs at a single center between June 20, 2020, and November 24, 2020. The ECMO-free protocol included three phases: (1) the safety screening, (2) non-ECMO Fio2 titration, and (3) the ECMO-free trial. Enrollment, interventions, and data collection were performed prospectively by trained study staff. RESULTS: Twenty-six patients received the ECMO-free protocol on 385 patient-days. The safety screening was passed during a total of 59 ECMO-free daily assessments (15.3%) among 20 patients. Every passed safety screening proceeded to an ECMO-free trial. Twenty-eight passed ECMO-free trials (47.5%) occurred among 16 patients (61.5%). No missed safety screenings, protocol deviations, or adverse events occurred. Of the 16 patients who passed an ECMO-free trial, 14 patients (87.5%) were decannulated. Among decannulated patients, 12 patients (85.7%) were decannulated on the same day as a passed ECMO-free trial, 6 patients (42.9%) were decannulated on the first day that they passed an ECMO-free trial, and 6 patients (42.9%) passed an ECMO-free trial at least twice consecutively before decannulation. The median time from first passed ECMO-free trial to decannulation was 2 days (interquartile range, 0-3 days). INTERPRETATION: The ECMO-free protocol is feasible and may identify patients for decannulation earlier than gradual approaches to weaning.
BACKGROUND: Decannulation from venovenous extracorporeal membrane oxygenation (ECMO) at the earliest and safest possible time may improve outcomes and reduce cost. Yet, no prospective studies have compared weaning strategies for liberation from ECMO. RESEARCH QUESTION: Is a protocolized daily assessment of readiness to liberate from venovenous ECMO safe and feasible? STUDY DESIGN AND METHODS: We conducted a prospective, single-arm safety and feasibility study of a protocol for daily assessment of readiness to liberate from venovenous ECMO among consecutive adult patients receiving venovenous ECMO across four ICUs at a single center between June 20, 2020, and November 24, 2020. The ECMO-free protocol included three phases: (1) the safety screening, (2) non-ECMO Fio2 titration, and (3) the ECMO-free trial. Enrollment, interventions, and data collection were performed prospectively by trained study staff. RESULTS: Twenty-six patients received the ECMO-free protocol on 385 patient-days. The safety screening was passed during a total of 59 ECMO-free daily assessments (15.3%) among 20 patients. Every passed safety screening proceeded to an ECMO-free trial. Twenty-eight passed ECMO-free trials (47.5%) occurred among 16 patients (61.5%). No missed safety screenings, protocol deviations, or adverse events occurred. Of the 16 patients who passed an ECMO-free trial, 14 patients (87.5%) were decannulated. Among decannulated patients, 12 patients (85.7%) were decannulated on the same day as a passed ECMO-free trial, 6 patients (42.9%) were decannulated on the first day that they passed an ECMO-free trial, and 6 patients (42.9%) passed an ECMO-free trial at least twice consecutively before decannulation. The median time from first passed ECMO-free trial to decannulation was 2 days (interquartile range, 0-3 days). INTERPRETATION: The ECMO-free protocol is feasible and may identify patients for decannulation earlier than gradual approaches to weaning.
Authors: Alain Combes; David Hajage; Gilles Capellier; Alexandre Demoule; Sylvain Lavoué; Christophe Guervilly; Daniel Da Silva; Lara Zafrani; Patrice Tirot; Benoit Veber; Eric Maury; Bruno Levy; Yves Cohen; Christian Richard; Pierre Kalfon; Lila Bouadma; Hossein Mehdaoui; Gaëtan Beduneau; Guillaume Lebreton; Laurent Brochard; Niall D Ferguson; Eddy Fan; Arthur S Slutsky; Daniel Brodie; Alain Mercat Journal: N Engl J Med Date: 2018-05-24 Impact factor: 91.245
Authors: April A Grant; Valerie J Hart; Edward B Lineen; Amit Badiye; Patricia M Byers; Amit Patel; Rodrigo Vianna; Michael M Koerner; Aly El Banayosy; Matthias Loebe; Ali Ghodsizad Journal: Artif Organs Date: 2018-01-18 Impact factor: 3.094
Authors: A Esteban; F Frutos; M J Tobin; I Alía; J F Solsona; I Valverdú; R Fernández; M A de la Cal; S Benito; R Tomás Journal: N Engl J Med Date: 1995-02-09 Impact factor: 91.245
Authors: E W Ely; A M Baker; D P Dunagan; H L Burke; A C Smith; P T Kelly; M M Johnson; R W Browder; D L Bowton; E F Haponik Journal: N Engl J Med Date: 1996-12-19 Impact factor: 91.245
Authors: Laveena Munshi; Allan Walkey; Ewan Goligher; Tai Pham; Elizabeth M Uleryk; Eddy Fan Journal: Lancet Respir Med Date: 2019-01-11 Impact factor: 30.700
Authors: L Brochard; A Rauss; S Benito; G Conti; J Mancebo; N Rekik; A Gasparetto; F Lemaire Journal: Am J Respir Crit Care Med Date: 1994-10 Impact factor: 21.405
Authors: Cecile Aubron; Allen C Cheng; David Pilcher; Tim Leong; Geoff Magrin; D Jamie Cooper; Carlos Scheinkestel; Vince Pellegrino Journal: Crit Care Date: 2013-04-18 Impact factor: 9.097
Authors: Elias H Pratt; Sarah Mausert; Michael D Wilson; Logan J Emerson; Neelima Navuluri; Aaron M Pulsipher; Amanda Brucker; Cynthia L Green; Desiree K Bonadonna; Benjamin S Bryner; Craig R Rackley Journal: Crit Care Explor Date: 2021-12-03